Press release
Advanced Cervical Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
Key Takeaways from the Advanced Cervical Cancer Pipeline Report
* DelveInsight's Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Advanced Cervical Cancer treatment.
* The leading companies working the Advanced Cervical Cancer Market include AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies, and others.
* Promising Advanced Cervical Cancer Pipeline Therapies in the various stages of development include Durvalumab, Cisplatin, Carboplatin, IBI310, and others.
* May 2024:- AstraZeneca- A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical). This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIC to IVA cervical cancer with lymph node involvement) who have not progressed following platinum-based CCRT.
* May 2024:- Incyte Corporation- A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies. This is a multicenter, open-label, single-arm study to investigate the safety, tolerability, PK, pharmacodynamics and preliminary activity of INCA32459 in participants with selected advanced malignancies. Part 1 (dose escalation) will determine the recommended dose of INCA 32459 for expansion (RDE) and the maximum tolerated dose (MTD).
Request a sample and discover the recent advances in Advanced Cervical Cancer @ Advanced Cervical Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/advanced-cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Advanced Cervical Cancer Overview
Advanced cervical cancer means the cancer has spread from the cervix to another area of the body such as the lungs. Sometimes cancer is advanced when it is first diagnosed. Unfortunately advanced cancer can't usually be cured. But treatment might control it, help symptoms, and improve your quality of life for a while. The most common places for cervical cancer to spread is to the lymph nodes, liver, lungs and bones. Treatment for advanced cervical cancer depends on the size of the cancer and where it is in the body. Chemotherapy can be used to treat advanced cervical cancer. Some women may have an operation called pelvic exenteration for cervical cancer that has come back within the pelvis.
Advanced Cervical Cancer Emerging Drugs Profile
* Imfinzi (durvalumab): AstraZeneca
* Dostarlimab: GlaxoSmithKline
* Andes 1537: Andes Biotechnologies
Learn more about Advanced Cervical Cancer in clinical trials @ Advanced Cervical Cancer Drugs [https://www.delveinsight.com/sample-request/advanced-cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Advanced Cervical Cancer Pipeline Therapeutics Assessment
There are approx. 70+ key companies which are developing the therapies for Advanced Cervical Cancer. The Advanced Cervical Cancer companies which have their Advanced Cervical Cancer drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.
DelveInsight's Advanced Cervical Cancer pipeline report covers around 75+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Discover more about Advanced Cervical Cancer in development @ Advanced Cervical Cancer Clinical Trials [https://www.delveinsight.com/sample-request/advanced-cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Advanced Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
Advanced Cervical Cancer Pipeline Products have been categorized under various Molecule types such as-
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
To know more about Advanced Cervical Cancer, visit @ Advanced Cervical Cancer Segmentation [https://www.delveinsight.com/sample-request/advanced-cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Advanced Cervical Cancer Pipeline Report
* Coverage- Global
* Advanced Cervical Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Advanced Cervical Cancer Therapeutics Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Advanced Cervical Cancer Companies- AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies, and others.
* Advanced Cervical Cancer Pipeline Therapies- Durvalumab, Cisplatin, Carboplatin, IBI310, and others.
For further information on the Advanced Cervical Cancer Pipeline Therapeutics, reach out @ Advanced Cervical Cancer Products Development [https://www.delveinsight.com/sample-request/advanced-cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Advanced Cervical Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Advanced Cervical Cancer - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Advanced Cervical Cancer Collaboration Deals
* Late Stage Products (Phase III)
* Durvalumab: AstraZeneca
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Dostarlimab: GlaxoSmithKline
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Andes 1537: Andes Biotechnologies
* Drug profiles in the detailed report.....
* Inactive Products
* Advanced Cervical Cancer Key Companies
* Advanced Cervical Cancer Key Products
* Advanced Cervical Cancer- Unmet Needs
* Advanced Cervical Cancer- Market Drivers and Barriers
* Advanced Cervical Cancer- Future Perspectives and Conclusion
* Advanced Cervical Cancer Analyst Views
* Advanced Cervical Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-cervical-cancer-pipeline-fda-approvals-unmet-needs-preclinical-and-discovery-stage-product-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Cervical Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated) here
News-ID: 3494867 • Views: …
More Releases from ABNewswire
Pixazo Launches Unified Visual AI API to Power the Next Generation of Multimodal …
Pixazo launches a Unified Visual AI API offering one-key access to 600+ models for image, video, audio, avatar, lip sync, and virtual try-on generation.
New Delhi, India - November 18, 2025 - Pixazo [https://www.pixazo.ai/] today announced the launch of its Unified Visual AI API, a single-key platform engineered to power the next great leap in digital creativity. As the world moves beyond text-based intelligence and into a multimodal era, Pixazo aims…
A Little Laughter, A Lot of Heart: Hannah's Docs & Ducks Reminds Families Why Re …
There's something special about a book that makes both kids and adults laugh at the same time. Docs & Ducks: A Quakery of Poems by Hannah is exactly that kind of book. It's light, funny, and a little bit thoughtful in ways you don't expect until you've turned the page.
The poems are short and easy to read, the kind you can slip into a bedtime routine or a classroom break.…
Matthew Mettias - Hawaii-born Sound Artist, Poet, and Creative Technologist - Em …
STANFORD, CA - November 18, 2025 - Hawaii-born, California-based sound artist, poet, composer, producer, and creative technologist, Matthew Mettias, is rapidly gaining international attention with a creative practice that blends island memory, cinematic sound, and ecopsychic healing. This month, his newest release reached #8 on Iceland's Top 100 Songs, marking a global breakthrough for the rising artist.
Raised in Honolulu and now a Stanford University alumnus, Mettias bridges his roots with…
XMO Corp CTO & Cofounder Brian Alvara to Speak on Digital Literacy and Tech Flue …
Washington, D.C. - November 18, 2025 - XMO Corp proudly announces that Brian Alvara, Chief Technology Officer and Cofounder, will be a featured speaker at the upcoming panel discussion, hosted by 2025 CHCI Tech Summit "?Hablas Tech?/Do You Speak Tech?", taking place on November 19, 2025, from 10:45 AM - 11:45 AM ET at Capital Turnaround, 700 M St SE, Washington, DC 20003.
The session will address one of the most…
More Releases for Advanced
Advanced Oxidation Technologies Market Size, Share 2021, Impressive Industry Gro …
The Advanced Oxidation Technologies Market is poised to take off in upcoming years hence showing a highly positive outlook through 2020-2028, according to a recently released report. Advanced Oxidation Technologies Market report covers industry chain analysis, latest market trends & dynamics along with cost profit analysis of major key players which focuses on expansion rate, prices, competition, size, prices, and value chain analysis of those leaders in the market.
The…
Medical Ceramics Market Analysis and Industry Forecast | Advanced Ceramics Resea …
Allied Market Research published a new report, titled, “Medical Ceramics Market by Type (Aluminum Oxide, Zirconia, and Carbon, Hydroxyapatite, Glass & Bioglass, Zirconia Alumina, Bioresorbable Ceramics, and Piezo Ceramics), by Application (Surgical Instruments, Diagnostic Equipment, Orthopedic Implants, Electronic Implants, Dental Implants, Disposables, and Packaging) – Global Opportunity Analysis and Industry Forecast, 2014 – 2022.” The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segment, Porter’s Five…
Skincell Advanced Reviews – Does Skincell Advanced Really Work?
People want clear, blemish-free skin! However, most people have skin tags, moles, and warts. Some causes are known, while some blemishes are caused without any reason at all. When a regular skincare regimen fails, people turn to costly surgeries and medications. Cleansing and moisturizing might not work well for all. All skin types are not the same, and toners and skincare creams seldom give long-lasting benefits.
Get Skincell Advanced From Its…
Global Advanced Oxidation Technologies Market 2019- 2025 || A-Zone Technologies, …
Synopsis of the Advanced Oxidation Technologies Market:
Latest Report on Advanced Oxidation Technologies Market deliberates the effect of various Factors influencing the market growth and drivers. Its further sheds light on market overview, key manufacturers, strategic adopted by them, size, latest trends and types, revenue, gross margin with regional analysis and forecast to 2025.
Overview of the Advanced Oxidation Technologies Market Report:
Advanced Oxidation Technologies Market report includes knowledge about the market overview…
Global Advanced Materials Market - 3M Company, DowDuPont Inc, Hexcel Corporation …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market - By Product type (Structural Material, Functional Material, Emerging Material) By End User (Building & Construction, Automotive, Aerospace, Defense, Marine, Electrical & Electronics, Healthcare, Oil & Gas and Energy, Others) & Global Region - Market Size, Trends, Share and Forecast 2018-2023” research report will include all the major trends and technologies that…
Global Advanced Materials Market: 3M Company, DowDuPont Inc, Hexcel Corporation, …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market 2017: Market Size, Trends & Opportunity Outlook – Forecast to 2023” research report will include all the major trends and technologies that play an important role in market growth in the predicted span of 6 years. It also presents the overview of industry players, advantages, challenges the business is going through. The…
